IDEAYA Biosciences (IDYA) Price & Analysis

Compare

616 Followers

IDYA Stock Chart & Stats

$28.64

$0.01(0.06%)

At close: Jan 08 4:00 PM EST

$28.64

$0.01(0.06%)

Day’s Range― - ―

52-Week Range$13.45 - $32.67

Previous CloseN/A

Volume96.34K

Average Volume (3M)1.35M

Market Cap

$2.67B

Enterprise Value$1.22B

Total Cash (Recent Filing)$669.74M

Total Debt (Recent Filing)$26.60M

Price to Earnings (P/E)―

Beta1.55

Next Earnings

Nov 11, 2025

EPS Estimate

-0.83

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.88

Shares Outstanding87,643,684

10 Day Avg. Volume1,495,185

30 Day Avg. Volume1,346,104

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)1.98

Price to Sales (P/S)299.87

P/FCF Ratio-8.35

Enterprise Value/Market Cap0.45

Enterprise Value/Revenue173.79

Enterprise Value/Gross Profit191.37

Enterprise Value/Ebitda-3.18

Forecast

1Y Price Target

$48.13

Price Target Upside68.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering17

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe ESMO data derisks IDYA’s Ph3 trial, as both pivotal endpoints of vision and eye preservation are trending favorably.

Treatment OutcomesA significant enhancement in vision was demonstrated for the pooled PB/EN cohort, with a gain of 10-17 letters, indicating a positive trend in treatment outcomes.

Bears Say

Clinical RisksRisks to the rating and price target include potential clinical setbacks for darovasertib and longer-than-anticipated path to market.

Investor ConcernsSome investors want to see evidence of vision preservation through long-term outcomes data rather than simulated reductions.

IDEAYA Biosciences News

Ideaya Biosciences price target raised to $79 from $74 at JPMorgan

JPMorgan raised the firm’s price target on Ideaya Biosciences (IDYA) to $79 from $74 and keeps an Overweight...

1d ago

IDYA

Ideaya Biosciences price target raised to $30 from $27 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Ideaya Biosciences (IDYA) to $30 from $27 and keeps a...

3d ago

IDYA

Ideaya Biosciences price target raised to $41 from $38 at RBC Capital

RBC Capital raised the firm’s price target on Ideaya Biosciences (IDYA) to $41 from $38 and keeps an...

3d ago

IDYA

Ideaya Biosciences presents clinical data from OptimUM-09 trial

Ideaya Biosciences (IDYA) presented clinical data from their ongoing Phase 2 OptimUM-09 trial of neoadjuvant darovasertib in patients...

4d ago

IDYA

Ideaya Biosciences reports overall survival data from darovasertib trial

Ideaya Biosciences (IDYA) announced the first reported median overall survival results from their Phase 1/2 clinical trial evaluating...

4d ago

PFE

IDYA

JPMorgan places ‘Positive Catalyst Watch’ on Ideaya into updates

JPMorgan analyst Anupam Rama added a “Positive Catalyst Watch” on shares of Ideaya Biosciences (IDYA) into the updates...

29d ago

IDYA

Promising Potential of IDEAYA Biosciences’ Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials

Analyst Justin Zelin of BTIG reiterated a Buy rating on IDEAYA Biosciences, retaining the price target of $62.00....

3d ago

IDYA

IDEAYA Biosciences Presents Promising Phase 2 Data

IDEAYA Biosciences ( ($IDYA) ) has provided an update. On October 17, 2025, IDEAYA Biosciences announced positive median...

4d ago

IDYA

IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy Rating

IDEAYA Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yigal Nochomovitz from...

4d ago

IDYA

Promising Potential of IDEAYA Biosciences: Strong Efficacy and Financial Stability Support Buy Rating

LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences today and set a price target...

7d ago

IDYA

IDEAYA Biosciences: Promising Outlook for Darovasertib in Uveal Melanoma Drives Buy Rating

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on IDYA stock, giving a Buy rating yesterday....

16d ago

IDYA

Ideaya Biosciences Advances IDE849 Study for DLL3-Expressing Tumors

Ideaya Biosciences (($IDYA)) announced an update on their ongoing clinical study. Ideaya Biosciences is conducting a clinical study...

28d ago

IDYA

Promising Developments in IDEAYA Biosciences’ Pipeline Drive Buy Rating with $74 Price Target by 2026

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on IDYA stock, giving a Buy rating on...

29d ago

IDYA

Ideaya Biosciences initiated with a Buy at Guggenheim

Guggenheim analyst Paul Jeng initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $50 price target...

1M ago

IDYA

IDYA FAQ

What was IDEAYA Biosciences’s price range in the past 12 months?

IDEAYA Biosciences lowest stock price was $13.45 and its highest was $32.67 in the past 12 months.

What is IDEAYA Biosciences’s market cap?

IDEAYA Biosciences’s market cap is $2.67B.

When is IDEAYA Biosciences’s upcoming earnings report date?

IDEAYA Biosciences’s upcoming earnings report date is Nov 11, 2025 which is in 18 days.

How were IDEAYA Biosciences’s earnings last quarter?

IDEAYA Biosciences released its earnings results on Aug 05, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.782 by -$0.098.

Is IDEAYA Biosciences overvalued?

According to Wall Street analysts IDEAYA Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does IDEAYA Biosciences pay dividends?

IDEAYA Biosciences does not currently pay dividends.

What is IDEAYA Biosciences’s EPS estimate?

IDEAYA Biosciences’s EPS estimate is -0.83.

How many shares outstanding does IDEAYA Biosciences have?

IDEAYA Biosciences has 87,643,684 shares outstanding.

What happened to IDEAYA Biosciences’s price movement after its last earnings report?

IDEAYA Biosciences reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.782. Following the earnings report the stock price went down -3.52%.

Which hedge fund is a major shareholder of IDEAYA Biosciences?

Currently, no hedge funds are holding shares in IDYA

IDEAYA Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-35.09%

Trailing 12-Months

Asset Growth

6.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

IDEAYA Biosciences

IDEAYA Biosciences (IDYA) is a biotechnology company focused on the discovery and development of targeted therapeutics for cancer and other genetic diseases. The company specializes in precision medicine, leveraging its proprietary drug discovery platforms to identify and develop small molecule therapeutics that target specific genetic mutations and pathways. IDEAYA operates primarily in the oncology sector and is committed to advancing innovative treatment options for patients with unmet medical needs.

IDEAYA Biosciences (IDYA) Earnings & Revenues

Historic Earnings Reports

IDYA Stock 12 Month Forecast

Average Price Target

$48.13

▲(68.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","80":"$80","29.75":"$29.8","46.5":"$46.5","63.25":"$63.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$79.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,29.75,46.5,63.25,80],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.36,31.33230769230769,35.30461538461538,39.276923076923076,43.24923076923077,47.22153846153846,51.19384615384615,55.16615384615385,59.13846153846154,63.11076923076923,67.08307692307693,71.05538461538461,75.0276923076923,{"y":79,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.36,28.95769230769231,30.555384615384614,32.153076923076924,33.75076923076923,35.348461538461535,36.94615384615385,38.543846153846154,40.14153846153846,41.73923076923077,43.33692307692308,44.934615384615384,46.5323076923077,{"y":48.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.36,27.563076923076924,27.766153846153845,27.96923076923077,28.17230769230769,28.375384615384615,28.57846153846154,28.78153846153846,28.984615384615385,29.18769230769231,29.39076923076923,29.593846153846155,29.796923076923076,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.73,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >